This includes people taking insulin or sulfonylureas, patients with diabetes, patients on blood pressure medications, patients with kidney disease or dehydration risk, patients with a gallbladder history, patients with significant reflux or gastroparesis symptoms, patients with eating disorder history, and patients who have difficulty meeting protein or fluid needs
The estimated annual cost of obesity in Canadaincluding hospitalizations, medications, long-term care, and premature mortalityis approximately $27 billion per year
This marks the world's first approved "PD-1+ADC" combination therapy
Market Segmentation Global Glucagon-Like Peptide-1 Agonists Market Size, Share & Industry Analysis, By Product Type (Short-Acting GLP-1 Agonists, Long-Acting GLP-1 Agonists), By Route of Administration (Injectable, Oral), By Application (Type 2 Diabetes, Obesity Management, Cardiovascular Disease Management), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), Analysis and Forecast 20262035 Global Glucagon-Like Peptide-1 Agonists Market Size & Statistics The Market size of global glucagon-like peptide-1 agonists was estimated to be worth USD 46.18 Billion in 2025
Gut Microbes, 14 (1), 2152307
